ADMA Share Price Performance
US$17.18
-4.00 (-18.89%)
37.0% undervalued intrinsic discount
US$27.25
Fair Value
Price US$17.18
AnalystConsensusTarget US$27.25
AnalystLowTarget US$19.98
AnalystHighTarget US$35.00
Fair ValueUS$27.25
Share Pricen/a
ADMA Biologics, Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 84 Fair Values set on narratives written by author
ADMA Community Narratives
AN
Fair Value US$27.25 37.0% undervalued intrinsic discount
Share Repurchase And Higher Margins Will Drive Future Upside Potential
1users have liked this narrative
0users have commented on this narrative
29users have followed this narrative
AN
Fair Value US$19.24 10.7% undervalued intrinsic discount
Concentrated Plasma Reliance Will Strain Operations Yet Spark Opportunity
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$35 50.9% undervalued intrinsic discount
Aging Population And Plasma Supply Will Drive Industry Expansion
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Valuation analysis
11-NOV-2024 Actual company guidance: 2024: 415 MUSD revenue (S24) and net income 120 MUSD (E24), 2025: 465 MUSD (S25), 165 MUSD net income (E25) Market cap of 5.35 BUSD (P) at 22.62/share: P/S24 = 12.9, P/E24 = 44.6, P/S25 = 11.5 and P/E25 = 32.4) My assumptions: ADMA will be highly profitable due to high ratio of hyperimmunes (maybe eventually they will only manufacture hyperimmunes if S. pneumonia is successful and provided they can source the required amount of hyperimmune plasma).Read more
2users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
PI
US$20.93
17.9% undervalued intrinsic discount
pizzitaxi Fair Value
Revenue growth
26% p.a.
Profit Margin
30%
Future PE
26x
Share price in 2029
US$29.36
Share Repurchase And Higher Margins Will Drive Future Upside Potential
Key Takeaways Adoption of manufacturing improvements, capacity expansions, and new products is driving margin growth, revenue diversification, and improved supply chain resilience. Enhanced liquidity from refinancing and strong market demand underpins strategic growth initiatives and positions the company for sustained earnings improvement.Read more
1users have liked this narrative
0users have commented on this narrative
29users have followed this narrative
AN
US$27.25
37.0% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
24.38% p.a.
Profit Margin
41.14%
Future PE
20.9x
Share price in 2028
US$33.28
Concentrated Plasma Reliance Will Strain Operations Yet Spark Opportunity
Key Takeaways Heavy reliance on plasma-derived products and a concentrated portfolio exposes the company to emerging therapies, regulatory risks, and market volatility. Increasing competition, regulatory scrutiny, and rising operational expenses may restrict market share growth, compress margins, and hinder long-term financial performance.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$19.24
10.7% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
22.29% p.a.
Profit Margin
37.43%
Future PE
17.68x
Share price in 2028
US$23.38
Aging Population And Plasma Supply Will Drive Industry Expansion
Key Takeaways Enhanced production processes and expanded plasma supply position the company for faster revenue growth and margin improvements beyond current market expectations. Strong demand drivers, strategic investments, and financial flexibility support sustained market share gains and shareholder returns.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$35
50.9% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
27.41% p.a.
Profit Margin
37.95%
Future PE
28.05x
Share price in 2028
US$42.52
Recently Updated Narratives
PI
Valuation analysis
Fair Value: US$20.93 17.9% undervalued intrinsic discount
11 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Share Repurchase And Higher Margins Will Drive Future Upside Potential
Fair Value: US$27.25 37.0% undervalued intrinsic discount
29 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Population And Plasma Supply Will Drive Industry Expansion
Fair Value: US$35 50.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
ADMA Biologics, Inc. Key Details
About ADMA
- Founded
- 2004
- Employees
- 685
- CEO
- WebsiteView website
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
